NTRA · Natera, Inc.
Is NTRA setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Natera, Inc., in one place.
Today's breakout radarIs NTRA setting up for a breakout?
Breakout Radar API →NTRA reports earnings on Nov 5, 2026 — a breakout right before a report can reverse on the numbers.
Not today. NTRA is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about NTRA?
Stock Sentiment API →Bulls: Roth/MKM initiated Natera at Buy with a $475 price target, betting on growing demand for cancer residual disease testing. Signatera Genome with phased and structural variants was highlighted in an ESMO Presidential Symposium, supporting the role of MRD-guided treatment in bladder cancer. The stock shows a relative-strength rating of 97 out of 99 among the 391 largest stocks (1 month -1.9%, 3 months +60.5%, 6 months +98.1%), with one screen citing RS 98 at $404.90 and +59.5% over 3 months; it sits in a tight setup above all key moving averages, with volume drying up as the daily 9 and 21 EMAs converge, and Druckenmiller bought in Q3 2024 at ~$127 versus ~$404 now.
Bears: Critics argue Signatera's use is out of control and becoming one of the biggest waste and rip-offs in the US health system, with one post claiming a quarter of MDs who use Signatera give promotional talks to Natera, targeting particularly surgeons whose 80% of orders are useless. Insider selling: 7 insiders sold $5.2M in shares over 7 days. Technically, the stock failed to break its 21 EMA and pulled back to 400 at the top of the buy zone, with 380 cited as the level that would mean 'broken.'
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about NTRA?
News Sentiment API →No recent news reading for NTRA. The News Sentiment API reads today's headlines on any US stock.
Are NTRA insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Sheena Jonathan$69K · Oct 21, 2026
- Sold · Sheena Jonathan$106K · Oct 21, 2026
- Sold · Sheena Jonathan$52K · Oct 21, 2026
- Sold · Sheena Jonathan$87K · Oct 21, 2026
- Sold · Sheena Jonathan$249K · Oct 21, 2026
How is Natera, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $752.8M | +38% | −$67.0M | $-0.47 |
| Mar 31, 2026 | $696.6M | +39% | −$85.1M | $-0.60 |
| Sep 30, 2025 | $592.2M | +35% | −$87.5M | $-0.64 |
| Jun 30, 2025 | $546.6M | +32% | −$100.9M | $-0.74 |
From the company's SEC filings (10-Q and 10-K).
What does Natera, Inc. expect?
Company Guidance API →- 2026 · total revenue · 8-K filed Aug 6, 2026
“Natera anticipates 2026 total revenue of $2.85 billion to $2.91 billion”
- 2026 · gross margin · 8-K filed Aug 6, 2026
“2026 gross margin 1 to be approximately 64% to 66%”
- 2026 · selling, general and administrative costs · 8-K filed Aug 6, 2026
“selling, general and administrative costs to be approximately $1.125 billion to $1.225 billion”
- 2026 · research and development costs · 8-K filed Aug 6, 2026
“research and development costs to be $800 million to $900 million”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.